27.01.2022 | COVID-19 | Commentary
It’s a marathon not a sprint: the need for long-term monitoring of myocardial dysfunction in COVID-19
verfasst von:
Vien T. Truong, Cassady Palmer, Eugene S. Chung, Wojciech Mazur
Erschienen in:
The International Journal of Cardiovascular Imaging
|
Ausgabe 5/2022
Einloggen, um Zugang zu erhalten
Excerpt
Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a pressing global public health issue. More specifically, the increased morbidity and mortality secondary to cardiac complications in COVID-19 has become concerning. Myocardial injury, defined by elevated troponin levels, is seen in up to 20–30% of patients hospitalized with COVID-19 [
1]. However, the exact mechanism of myocardial injury in COVID-19 has yet to be fully elucidated and is likely multifactorial. Furthermore, the true incidence of COVID-19 related myocarditis has not been determined. Preexisting cardiovascular conditions, thrombotic events, hypoxemic pulmonary vasoconstriction, cytokine storm, increased pulmonary vascular resistance, endotheliitis, myocardial inflammation, and direct viral damage has been associated with COVID-19 related myocardial dysfunction [
2‐
5]. …